A novel coronavirus (2019-nCoV) has been featured on every headline this past week as the WHO declares the outbreak a global public-health emergency. The 2019-nCoV causes illness ranging from the common cold to mores severe diseases such as Severe Acute Respiratory Syndrome (SARS), which can spread from person-to-person. The CDC believes that symptoms may appear in as few as 2 days or as long as 14 days after exposure. Common symptoms include a fever, cough, shortness of breath and breathing difficulties. In more severe cases, infection can cause pneumonia, severe respiratory issues, kidney failure and even death.
The 2019-nCoV was first identified in Wuhan, China on December 31, 2019. It quickly traveled around the world and the United States reported its first case on January 21, 2020. Since the break out (as of January 30th), over 7,800 people have been infected and 170 people have died, according to statistics. However, scientists believe that the real number is likely higher.
There is currently no vaccine to protect against the 2019-nCoV, nor any specific antiviral treatment. The best way to prevent the infection is to avoid being exposed to the virus. Government scientists in China, the United States and Australia, as well as those working at Johnson & Johnson, Moderna Therapeutics and Inovio Pharmaceuticals are all working quickly to develop a new vaccine. According to the New York Times, “The hunt began January 10th, when Chinese scientists posted the genetic make-up of the virus on a public database. The next morning, researchers at the National Institute of Health’s Vaccine Research Center in Maryland went to work. Within hours, they had pinpointed the parts of the genetic code that could be used to make a vaccine.”
Despite the quick response from several teams of scientist around the world, creating a vaccine for the 2019-nCoV can be a very long and expensive process. The first step is to identify the natural or synthetic antigens that might help prevent it. Then scientist will study how it interacts on a cellular level. After they are able to identify that it will be safe and effective for humans, clinical trials begin for Phases 1 – 3 research. After a successful Phase 3 trial (which could take up to several months or years), the manufacturer will submit for a license through the FDA, and it will be available for the general public. The only way to create a vaccine and determine if it is effective is to perform research studies at sites similar to Rochester Clinical Research, and provide the data to confirm that a vaccine is safe and effective. If you would like to help advance medicine and change lives and join a vaccine research study, please see below what we have available . Be sure to check back often, as we have new studies starting all the time.
Rochester Clinical Research is currently seeking participants between the ages of 18-50 years old to participate in a Dengue Fever vaccine study. The study is 1 year long and consists of 8 visits to our office. You will be compensated up to $150 per visit for your time and travel to participate. View Trial Details
Rochester Clinical Research is looking for volunteers 65 years or older to participate in a flu vaccine research study. The study is approximately 12 months long and consists of 5 to 7 visits to our office. You will be compensated $165 per visit for your time and travel to participate. View Trial Details
Rochester Clinical Research is currently looking for individuals to join a vaccine study for the varicella-zoster virus. Varicella is one of nine in the herpes class that can infect humans and causes chickenpox or shingles infections when it’s not prevented. The purpose of this study is to evaluate the safety and effectiveness of an mRNA vaccine against the virus. We are seeking participants between the ages of 50-69 years old who have not received a shingles vaccine already. This study is between 8-12 months long and includes at least 10 office visits. Compensation is available for $128 per office visit. View Trial Details
Rochester Clinical Research is currently seeking volunteers between the ages of 9-25 years old to participate in a preventative CMV vaccine study. The purpose of this study is to vaccinate children against the virus to prevent them from spreading it to adults, especially women that may be planning on becoming pregnant in the foreseeable future. The study is approximately 18 months long and includes 12 visits in total. View Trial Details
There is currently no vaccine to prevent or protect against Lyme. RCR is currently conducting a vaccine study to help prevent Lyme disease from infecting adolescents between the ages of 5 to 17. This study will last approximately 24 months with 6 visits to our RCR office and 2 telephone calls. View Trial Details
Rochester Clinical Research is currently seeking volunteers ages 50-59 years of age, who are at risk for chronic asthma/COPD, cardiovascular health hx, stroke/HA, and diabetes, to participate in an RSV (respiratory syncytial virus) vaccine study. This paid research study is testing the immune response and safety of a phase 3 vaccine. The study is about 12 months long and requires 4 visits to our office. If you qualify, you may be compensated for your time and travel to participate in the study. View Trial Details
Rochester Clinical Research is currently seeking volunteers who are 65 years and older for an Influenza vaccine study. The purpose of this study will be to evaluate the safety and immunogenicity of an mRNA vaccine to prevent influenza. Compensation for time and travel is available for around $630 to those who qualify. View Trial Details
Rochester Clinical Research is seeking volunteers who are 65 years and older to participate in an investigational mRNA flu vaccine study. The purpose of this study is to evaluate the effectiveness of using mRNA technology in an investigational flu vaccine and see if it protects against different variants. This is a phase 3 study and is about 12 months long with only one visit to our office. View Trial Details
Rochester Clinical Research is currently seeking born-female volunteers between the ages of 16 and 40 years old to participate in a CMV vaccine study. The purpose of this study is to find a safe and effective vaccine against Cytomegalovirus. View Trial Details